Apitegromab Shows Promise in Enhancing Motor Function in Spinal Muscular Atrophy Patients
New clinical trial results reveal that apitegromab significantly enhances motor function in patients with nonambulatory spinal muscular atrophy, offering hope for better treatment options.
Recent research published in the Lancet Neurology highlights the potential of apitegromab, a monoclonal antibody that inhibits myostatin activation, in improving motor function among patients with nonambulatory type 2 or type 3 spinal muscular atrophy (SMA). SMA is a genetic disorder characterized by progressive muscle weakness and degeneration, affecting motor skills and mobility.
In a phase 3 clinical trial conducted at 48 hospitals, researchers evaluated the safety and effectiveness of apitegromab in young patients aged 2 to 21 years who were already receiving standard treatments like nusinersen or risdiplam. The study enrolled 188 patients, with 128 receiving apitegromab and 60 receiving a placebo, administered every four weeks.
Results demonstrated that children aged 2 to 12 years treated with apitegromab experienced a significant improvement in motor function, measured by the Hammersmith Functional Motor Scale-Expanded (HFMSE), with a mean increase of 1.8 points from baseline over 12 months compared to placebo. The 20 mg/kg dosage showed a mean difference of 1.4 points, indicating a positive trend toward motor skill enhancement. Notably, the drug was well tolerated, with adverse events comparable to those seen in the placebo group, aligning with the typical safety profile for SMA therapies.
Dr. Thomas O. Crawford of Johns Hopkins Medicine and his colleagues concluded that apitegromab is effective in improving motor capabilities and is generally safe for patients with nonambulatory SMA. These findings support the potential use of muscle-targeting therapies to mitigate motor impairment in SMA patients. For more detailed information, refer to the full study in "The Lancet Neurology".
source: https://medicalxpress.com/news/2025-08-apitegromab-motor-function-spinal-muscular.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative PET Imaging Technique Identifies Early Heart Damage in Non-Ischemic Cardiomyopathy Patients
A new PET/CT imaging approach enables early detection of heart damage by visualizing fibroblast activation in patients with non-ischemic cardiomyopathy, promising improved diagnosis and management strategies.
Common Anti-Inflammatory Medication May Reduce Blood Mutations Linked to Heart Disease
Low-dose colchicine may slow the growth of harmful blood cell mutations linked to increased risk of heart disease and blood cancers, offering new potential for cardiovascular risk management.
Persistent Rural-Urban Disparities in Chronic Pain Highlighted by New Study
A new study highlights ongoing disparities in chronic pain between rural and urban populations in the U.S., emphasizing the need for innovative, accessible pain management strategies to address health inequities.
Limited Use of Genetic Testing for Children with Autism and Intellectual Disabilities in Medicaid Despite Guidelines
Despite clinical guidelines, genetic testing for children with autism and intellectual disabilities remains underutilized in Medicaid, with disparities affecting minority groups. A recent study urges policy and practice reforms to improve access and diagnosis.